Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer
T Okegawa, N Itaya, H Hara, M Tambo… - Anticancer …, 2014 - ar.iiarjournals.org
Aim: We examined whether Circulating Tumor Cells (CTCs) can be used to predict survival
in patients with bone-metastatic castration-resistant-prostate cancer (mCRPC) treated with …
in patients with bone-metastatic castration-resistant-prostate cancer (mCRPC) treated with …
Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel …
M Thalgott, MM Heck, M Eiber, M Souvatzoglou… - Journal of cancer …, 2015 - Springer
Purpose Circulating tumor cell (CTC) counts might display a superior prognostic value for
overall survival (OS) compared to objective response criteria (OR) in metastatic castration …
overall survival (OS) compared to objective response criteria (OR) in metastatic castration …
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
JS De Bono, HI Scher, RB Montgomery, C Parker… - Clinical cancer …, 2008 - AACR
Purpose: A method for enumerating circulating tumor cells (CTC) has received regulatory
clearance. The primary objective of this prospective study was to establish the relationship …
clearance. The primary objective of this prospective study was to establish the relationship …
[HTML][HTML] Value of early circulating tumor cells dynamics to estimate docetaxel benefit in metastatic castration-resistant prostate cancer (mCRPC) patients
R Lozano, D Lorente, IM Aragon, N Romero-Laorden… - Cancers, 2021 - mdpi.com
Simple Summary The prognostic role of CTC enumeration in mCRPC patients has been
established in several studies, demonstrating a higher prognostic performance than post …
established in several studies, demonstrating a higher prognostic performance than post …
Circulating tumor cells in a phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer
NJ Vogelzang, K Fizazi, JM Burke, R De Wit… - European urology, 2017 - Elsevier
Elevated circulating tumor cell (CTC) blood levels (≥ 5 cells/7.5 ml) convey a negative
prognosis in metastatic castration-resistant prostate cancer but their prognostic significance …
prognosis in metastatic castration-resistant prostate cancer but their prognostic significance …
Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC)
J Moreno, JS DeBono, D Shaffer… - Journal of clinical …, 2007 - ascopubs.org
5016 Background: Monitoring CTCs in patients undergoing therapy for metastatic breast
cancer is an effective means to predict outcome and monitor treatment. The primary …
cancer is an effective means to predict outcome and monitor treatment. The primary …
[HTML][HTML] Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, HT Arkenau, JE Ang, I Ledaki, G Attard… - Annals of oncology, 2009 - Elsevier
Background: The purpose of this study was to evaluate the association of circulating tumour
cell (CTC) counts, before and after commencing treatment, with overall survival (OS) in …
cell (CTC) counts, before and after commencing treatment, with overall survival (OS) in …
[HTML][HTML] Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in …
M Thalgott, B Rack, M Eiber, M Souvatzoglou… - BMC cancer, 2015 - Springer
Abstract Background Circulating tumor cell (CTCs) counts might serve as early surrogate
marker for treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) …
marker for treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) …
[PDF][PDF] The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer
TW Friedlander, L Fong - J Clin Oncol, 2014 - academia.edu
Although circulating tumor cells (CTCs) were first observed from patients with metastatic
malignancies more than 100 years ago, 1 only recently has the clinical and research …
malignancies more than 100 years ago, 1 only recently has the clinical and research …
Prognostic value of circulating tumor cells in castration resistant prostate cancer: a meta-analysis
Y Zheng, C Zhang, J Wu, G Cheng, H Yang, L Hua… - Urology …, 2016 - ojs3.sbmu.ac.ir
Purpose: The prognostic value of circulating tumor cells (CTC) detected in castration-
resistant prostate cancer (CRPC) is currently under debate. The aim of our meta-analysis …
resistant prostate cancer (CRPC) is currently under debate. The aim of our meta-analysis …
Related searches
- tumor cells docetaxel chemotherapy
- prostate cancer docetaxel chemotherapy
- prostate cancer tumor cells
- prostate cancer overall survival
- response assessment docetaxel chemotherapy
- prostate cancer mcrpc patients
- tumor cells response assessment
- tumor cells end of the beginning
- tumor cells surrogate for survival
- prostate cancer swog s0421
- prostate cancer end of the beginning
- swog s0421 overall survival
- docetaxel benefit mcrpc patients
- tumor cells docetaxel and prednisone
- prostate cancer docetaxel and prednisone
- prostate cancer docetaxel benefit